CD8A and neoplasm: Anti-TREML4 mAb-antigen conjugates can generate antigen-specific CD8+ and CD4+ T cell immunity to tumor and viral antigens (90), or antigen-specific tolerance (91), when targeted in the presence or absence of external adjuvant.